

**SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION**


<b>1. LICENSEE/LOCATION INSPECTED:</b>  <b>Missouri Cancer Associates, LLC</b> <b>1705 East Broadway</b> <b>Columbia, MO 65201</b>  REPORT NUMBER(S)                      2008-001		<b>2. NRC/REGIONAL OFFICE</b>  <b>U.S. Nuclear Regulatory Commission</b> <b>Region III</b> <b>2443 Warrenville Road</b> <b>Suite 210</b> <b>Lisle, Illinois 60532-4351</b>	
<b>3. DOCKET NUMBER(S)</b> 030-37082	<b>4. LICENSEE NUMBER(S)</b> 24-32604-01	<b>5. DATE(S) OF INSPECTION</b> MAY 20, 2008	

**LICENSEE:**  
 The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

- 1. Based on the inspection findings, no violations were identified.
- 2. Previous violation(s) closed.
- 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.


\_\_\_\_\_ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

- 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11. (Violations and Corrective Actions)



**Licensee's Statement of Corrective Actions for Item 4, above.**

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Sam Mulay		5/20/08

SAFETY INSPECTION REPORT  
AND COMPLIANCE INSPECTION

1. LICENSEE <b>Missouri Cancer Associates, LLC</b> REPORT NUMBER(S) <b>2008-001</b>		2. NRC/REGIONAL OFFICE <b>Region III</b> <b>2443 Warrenville Road, Suite 210</b> <b>Lisle, IL 60532</b>	
3. DOCKET NUMBER(S) <b>030-37082</b>	4. LICENSE NUMBER(S) <b>24-32604-01</b>	5. DATE(S) OF INSPECTION <b>May 20, 2008</b>	
6. INSPECTION PROCEDURES USED <b>87132</b>		7. INSPECTION FOCUS AREAS <b>03.01-03.07</b>	

## SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S) <b>2230</b>	2. PRIORITY <b>G2</b>	3. LICENSEE CONTACT <b>Mark Bryer, MD., RSO</b>	4. TELEPHONE NUMBER <b>573-442-5525</b>
-----------------------------------	--------------------------	--	--

<input checked="" type="checkbox"/> Main Office Inspection	Next Inspection Date: <b>May 2010</b>
<input type="checkbox"/> Field Office	
<input type="checkbox"/> Temporary Job Site Inspection	

## PROGRAM SCOPE

This active medical program performs approximately 200 fractionated HDR treatments monthly utilizing one Nucletron MicroSelectron Model 105.999, containing iridium-192 as authorized. Treatments involve primarily breast implants with occasional gynecological administrations. Currently, six medical physicists, seven authorized users, and two dosimetrists are involved in licensed activities.

The licensee does not maintained an inventory of licensed material equal to or greater then that specified in Table 1, Increased Controls Order dated November 2005. Although authorized, the licensee does not possess the strontium-90 eye applicator.

## Performance Observations

A patient treatment was observed during the inspection which included a review of the patient written directive, pre and post treatment surveys, availability of the RSO/authorized user and physicist, proper patient identification, etc. The treatment was delivered without incident. In addition, day of treatment operability checks were independently demonstrated and revealed proper operation of the unit and related safety systems including: source retract upon attempted entry, Primealert, source position indicators, intercom, availability of emergency source handling equipment and CCTV monitor with no problems or issues noted. Random record reviews of the licensee's quality management program revealed complete documentation for the HDR modality.

The licensee exchanges personal dosimetry quarterly. A record review of dosimetry readings for 2007 revealed whole-body and extremity readings of 47 mRem and 80 mRem respectively. YTD 2008 whole-body and extremity readings revealed 22 mRem and "0" mRem respectively.

Licensed material was observed adequately secured during the review and was not accessible to members of the general public. Independent measurements taken at the HDR surface revealed 0.2 mr/hr and approximately 0.03 mr/hr at 3 feet. Readings at the treatment console with the source exposed did not exceed 0.02 mr/hr. A side-by-side comparison between the NRC survey instrument and that used by the licensee revealed similar results.